Inhibikase Therapeutics Inc (FRA:IQT0)
€ 3.21 0 (0%) Market Cap: 5.05 Mil Enterprise Value: -14.25 Mil PE Ratio: 0 PB Ratio: 4.07 GF Score: 40/100

Q4 2023 Inhibikase Therapeutics Inc Earnings Call Transcript

Mar 28, 2024 / 12:00PM GMT
Operator

Ladies and gentlemen, thank you for standing by. Greetings, and welcome to Inhibikase Therapeutics fourth-quarter and full-year 2023 financial results. At this time, all participants will be in listen-only mode. A question-and-answer session will follow the formal presentation. Please note that today's conference is being recorded. (Operator Instructions)

I'll now turn the call over to Alex Lobo, Stern Investor Relations. Alex, you may now begin.

Alex Lobo
Inhibikase Therapeutics Inc - Investor Relations

Thank you, operator. Good morning, and welcome to Inhibikase Therapeutics fourth-quarter and full-year 2023 financial results conference call and audio webcast. With me today is Dr. Milton Werner, Chief Executive Officer; and Garth Lees-Rolfe, Chief Financial Officer.

On March 27, Inhibikase issued a press release announcing financial results for the fourth quarter and full year ended December 31, 2023. We encourage everybody to read yesterday's press release as well as Inhibikase's annual report on Form 10-K, which is being filed with the

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot